Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from 3SBio ( (HK:1530) ) is now available.
3SBio Inc. has announced a board meeting scheduled for August 29, 2025, to discuss and approve the company’s unaudited interim results for the first half of the year ending June 30, 2025. The meeting will also consider the potential payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.
The most recent analyst rating on (HK:1530) stock is a Hold with a HK$25.81 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.
More about 3SBio
3SBio Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development, manufacturing, and marketing of pharmaceutical products. The company is listed on the Hong Kong Stock Exchange and operates primarily in the healthcare industry.
Average Trading Volume: 54,167,795
Technical Sentiment Signal: Buy
Current Market Cap: HK$81.58B
For an in-depth examination of 1530 stock, go to TipRanks’ Overview page.